MétaCan
Menu
Back to cohort
Record W4395028698 · doi:10.1021/acsnano.3c06225

Nanoparticle Retinoic Acid-Inducible Gene I Agonist for Cancer Immunotherapy

2024· article· en· W4395028698 on OpenAlexfundno aff
Lihong Wang-Bishop, Mohamed Wehbe, Lucinda E. Pastora, Jinming Yang, Blaise R. Kimmel, Kyle M. Garland, Kyle W. Becker, Carcia S. Carson, Eric W. Roth, Katherine N. Gibson‐Corley, David Ulkoski, Venkata R. Krishnamurthy, Olga Fedorova, Ann Richmond, Anna Marie Pyle, John T. Wilson

Bibliographic record

VenueACS Nano · 2024
Typearticle
Languageen
FieldImmunology and Microbiology
TopicImmunotherapy and Immune Responses
Canadian institutionsnot available
FundersCongressionally Directed Medical Research ProgramsNational Institute of Diabetes and Digestive and Kidney DiseasesNational Cancer InstituteVanderbilt Digestive Diseases Research Center, Vanderbilt University Medical CenterDivision of Electrical, Communications and Cyber SystemsInternational Institute for Nanotechnology, Northwestern UniversityMaterials Research Science and Engineering Center, Harvard UniversityVanderbilt University Medical CenterDivision of Materials ResearchVanderbilt UniversityVanderbilt Institute of Nanoscale Science and Engineering, Vanderbilt UniversityDivision of Graduate EducationNorthwestern UniversityPharmaceutical Research and Manufacturers of America FoundationU.S. Department of Veterans AffairsNational Institutes of HealthVanderbilt-Ingram Cancer CenterCanadian Institutes of Health ResearchNational Science Foundation
KeywordsAgonistRetinoic acidCancer immunotherapyImmunotherapyCancerGeneCancer researchChemistryComputational biologyBiologyBiochemistryReceptorGenetics

Abstract

fetched live from OpenAlex

High Resolution Image Download MS PowerPoint Slide Pharmacological activation of the retinoic acid-inducible gene I (RIG-I) pathway holds promise for increasing tumor immunogenicity and improving the response to immune checkpoint inhibitors (ICIs). However, the potency and clinical efficacy of 5′-triphosphate RNA (3pRNA) agonists of RIG-I are hindered by multiple pharmacological barriers, including poor pharmacokinetics, nuclease degradation, and inefficient delivery to the cytosol where RIG-I is localized. Here, we address these challenges through the design and evaluation of ionizable lipid nanoparticles (LNPs) for the delivery of 3p-modified stem-loop RNAs (SLRs). Packaging of SLRs into LNPs (SLR-LNPs) yielded surface charge-neutral nanoparticles with a size of ∼100 nm that activated RIG-I signaling in vitro and in vivo. SLR-LNPs were safely administered to mice via both intratumoral and intravenous routes, resulting in RIG-I activation in the tumor microenvironment (TME) and the inhibition of tumor growth in mouse models of poorly immunogenic melanoma and breast cancer. Significantly, we found that systemic administration of SLR-LNPs reprogrammed the breast TME to enhance the infiltration of CD8 + and CD4 + T cells with antitumor function, resulting in enhanced response to αPD-1 ICI in an orthotopic EO771 model of triple-negative breast cancer. Therapeutic efficacy was further demonstrated in a metastatic B16.F10 melanoma model, with systemically administered SLR-LNPs significantly reducing lung metastatic burden compared to combined αPD-1 + αCTLA-4 ICI. Collectively, these studies have established SLR-LNPs as a translationally promising immunotherapeutic nanomedicine for potent and selective activation of RIG-I with the potential to enhance response to ICIs and other immunotherapeutic modalities.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.416
Threshold uncertainty score0.893

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.019
GPT teacher head0.284
Teacher spread0.265 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations24
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueACS NanoSame topicImmunotherapy and Immune ResponsesFrench-language works237,207